m+Medelevator.RU
← Поиск публикаций
Case reports in dentistry · 2026

Application of Patient-Specific PCL/βTCP Scaffolds for Reconstruction of Maxillomandibular Bone Defects: A Case Series.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Farajpour Hekmat, Boroojeni Helia Sadat Haeri, Mohaghegh Sadra, Nokhbatolfoghahaei Hanieh, Khojasteh Arash

Аннотация

AIM: This case series study was aimed at reporting reconstruction of maxillomandibular large bone defects using patient-specific polycaprolactone/β-tricalcium phosphate (PCL/βTCP) scaffolds.

MATERIAL AND METHOD: In three patients who underwent mandibular segmental resection, scaffolds were implanted to augment load-bearing areas while preserving the inferior alveolar neurovascular bundle continuity (functional bone replacement). In two other patients, PCL/TCP scaffolds were implanted in non-load-bearing areas to separate anatomic spaces (anatomic bone replacement). One anatomic scaffold was used as a covering membrane in posterior mandible atrophic ridge augmentation, and another was used to separate the orbital cavity from the antrum. Each patient underwent computed tomography (CT) scans before surgery and at the end of the follow-up period. Histological analyses were performed on biopsy samples collected from those who underwent placement of dental implants.

RESULTS: Radiologic analyses showed 30%-75% new bone formation in functional bone replacement. A proper bony border was created following anatomic bone replacement. Minor graft exposure and inflammation were observed in three patients. Histological analyses revealed proper scaffold degradation and bone formation.

CONCLUSION: Given the overall clinical complications in our study, PCL/βTCP patient-specific scaffolds can be potential treatment options in selected cases. However, further studies are warranted.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты